Abstract
Human anthrax vaccines currently licensed in the United States and Western Europe consist of alum-precipitated or aluminum hydroxide-adsorbed supernatant material from fermentor cultures of toxigenic, nonencapsulated strains of Bacillus anthracis. These vaccines have several drawbacks, including the need for frequent boosters, the apparent inability to protect adequately against certain strains of B. anthracis, and occasional local reactogenicity.
Studies are being undertaken to develop an improved human anthrax vaccine which is safe and efficacious, and which provides long-lasting immunity. Aspects being studied include the identification of antigens and epitopes responsible for eliciting protective immunity, the mechanisms of resistance to anthrax infection, the role of specific antibody in resistance, the differences in immunity elicited by living and chemical vaccines, the potential of new adjuvants to augment immunity, and the feasibility of developing safe vaccine strains having mutationally altered toxin genes. Both living and non-living (chemical) prototype vaccines are being developed and tested.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
AbalakinB.A., CherkasskiiB.L. (1978): The use of inbred mice as models for the indication and differentiation of Bacillus anthracis strains. - Zh. Microbiol. Epidemiol. Immunobiol., 55: 146–147.
AuerbachS., WrightG. (1955): Studies on immunity anthrax. VI. Immunizing activity of protective antigen against various strains of Bacillus anthracis. - J. Immunol., 75: 129–133.
BeallF.A., TaylorJ., ThorneC.B. (1962): Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. -J. Bacteriol., 83: 1274–1280.
BeltonF.C., StrangeR.E. (1954): Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. -Br. J. Exp. Pathol., 35: 144–152.
BerendtR., JemskiJ., Johnson-WinegarA., IvinsB. (1985): The use of toxin components for the immunoprophylaxis of inhalation anthrax. - Abstr. Ann. Meeting, Ann. Soc. Microbiol. E61, 85.
BiozziG., MoutonD., SigueiraM., StiffelC. (1985): Effect of genetic modification of immune responsiveness on anti-infection and anti-tumor resistance. In Genetic control of host resistance to infection and malignancy, E. Skamene Ed., Alan R. Liss. Inc., New York, pp. 3–18.
BrachmanP.S. (1970): Anthrax. - Ann. N.Y. Acad. Sci., 174: 577–582.
BrachmanP.S., GoldH., PlotkinS.A., FeketyF.R., WerrinM., IngrahamN.R. (1962): Field evaluation of a human anthrax vaccine. - Am. J. Public Health, 52: 632–645.
DeArmonI.A.Jr., KleinF., LincolnR.E., MahlandtB.G., FerneliusA.L. (1961): Immunological studies of anthrax. I. An index to determine quantitative immunization. - J. Immunol., 87: 233–239.
EzzellJ.W.E., IvinsB.E., LepplaS.H. (1984): Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. - Infect. Immun., 45: 761–767.
FerneliusA.L., DeArmonI.A.Jr., KleinF., LincolnR.E. (1960): Comparison of graded an quantal virulence tests for Bacillus anthracis spores. - J. Bacteriol., 79: 594–600.
FriedlanderA.M. (1986): Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. - J. Biol. Chem., 261: 7123–7126.
GladstoneG.P. (1946): Immunity to anthrax: prospective antigen present in cell-free culture filtrates. -Brit. J. Exp. Pathol., 27: 393–410.
GochenourW.S., SchoeningH.W., SteinC.D., MohlerW.M. (1935): Efficacy of anthrax biologics in producing immunity in previously unexposed animals.- U.S.D.A. Tech. Bull. 468: 1–15.
GraberC.D., GoustJ.M., GlassmanA.D., KendallR., LoadholtC.B. (1981): Immunomodulating properties of dimethylglycine in humans. - J. Infect. Dis., 143: 101–105.
GreenB.D., BattistiL., KoehlerT.M., ThorneC.B., IvinsB.E. (1985): Demonstration of a capsule plasmid in Bacillus anthracis. - Infect. Immun., 49: 291–297.
HainesB.W., KleinF., LincolnR.E. (1965): Quantitative assay for crude anthrax toxins. - J. Bacteriol., 89: 74–83.
HambletonP., CarmanJ.A., MellingJ. (1984): Anthrax: the disease in relation to vaccines. -Vaccine, 2: 125–132.
HoisethS.K., StockerB.A.D. (1981): Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. - Nature (London), 291: 238–239.
IvanovicsG. (1983): Immunity to anthrax. - Z. Immunitaet. Allerg. Klin. Immunol., 94: 436–458 (In English).
IvinsB.E., EzzellJ.W.Jr., JemskiJ., HedlundK., RistrophJ.D., LepplaS.H. (1986): Immunization studies with attenuated strains of Bacillus anthracis. -Infect. Immun., 52: 454–548.
IvinsB.E., WelkosS.L. (1986): Cloning and expression of the Bacillus anthravis protective antigen gene in Bacillus subtilis. - Infect. Immun., 54: 537–542.
IvinsB.E., WelkosS.L., KnudsonG.B., LeBlancD.J. (1988): Transposon Tn916 mutagenesis in Bacillus anthracis. - Infect. Immun., 56: 176–181.
JacksonF.C., WrightG.G., ArmstrongJ. (1957): Immunization of cattle against experimental anthrax with alum-precepitated protective antigen or spore vaccine. - Am. J. Vet. Res., 18: 771–777.
JonesW.I.Jr., KleinF., WalkerJ.S., MahlandtB.G., DobbsJ.P., LincolnR.E. (1967): In vivo growth and distribution of anthrax bacilli in resistant, susceptible, and immunized hosts. - J. Bacteriol., 94: 600–608.
KeppieJ., SmithH., Harris-SmithP.W. (1955): The chemical basis of the virulence of Bacillus anthracis. III. The role of the terminal bacteremia in death of guinea-pigs from anthrax. - Br. J. Exp. Pathol., 36: 315–322.
KeppieJ., Harris-SmithP.W., SmithH. (1963): The chemical basis of the virulence of Bacillus anthracis. IX. Its aggressins and their mode of action. - Br. J. Exp. Pathol., 44: 446–453.
KleinF., DeArmonI.A.Jr., LincolnR.E., MahlandtB.G., FerneliusA.L. (1962): Immunological studies of anthrax. II. Levels of immunity against Bacillus anthracis obtained with protective antigen and live vaccine. - J. Immunol., 88: 15–19.
KleinF., HainesB.W., MahlandtB.G., DeArmonI.A.Jr., LincolnR.E. (1963): Dual nature of resistance mechanisms as revealed by studies of anthrax septicemia. - J. Bacteriol., 85: 1032–1038.
LepplaS.H. (1982): Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. - Proc. Natl. Acad. Sci. U.S.A., 79: 3162–3166.
LepplaS.H. (1984): Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. In Advances in cyclic nucleotide and protein phosphorylation research, vol. 17., P. Greengard and G.A. Robinson Ed., Raven Press, New York, pp. 189–198.
LepplaS.H., IvinsB.E., EzzellJ.W.E.Jr. (1985): Anthrax toxin. In Microbiology — 1985, L. Leive Ed., American Society for Microbiology, Washington, D.C., pp. 63–66.
LincolnR.E., FishD.C. (1970): Anthrax toxin. In Microbial toxins, vol. 3, T.C. Montie, S. Kadis, and S.I. Ajl Ed., Academic Press, New York, pp. 361–414.
LincolnR.E., RhianM.A., KleinF., FerneliusA. (1961): Pathogenesis as related to physiological state of anthrax spore and cell. In Spores II, H.O. Halverson Ed., American Society for Microbiology, Washington, D.C., pp. 255–273.
LincolnR.E., WalkerJ.S., KleinF., RosenwaldA.J., JonesW.I.Jr. (1967): Value of field data for extrapolation in anthrax. - Fed. Proc., 26: 1558–1562.
LittleS.F., KnudsonG.B. (1986): Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. - Infect. Immun., 52: 509–512.
MahlandtB.G., KleinF., LincolnR.E., HainesB.W., JonesW.I.Jr., FriedmanR.H. (1966): Immunologic studies of anthrax. IV. Evaluation of the Immuno genicity of three components of anthrax toxin. -J. Immunol., 96: 727–733.
MikesellO.H.P., IvinsB.E., RistrophJ.D., DrierT.M. (1983): Evidence for plasmid-mediated toxin production in Bacillus anthracis. - Infect. Immun., 39: 371–376.
PasteurL. (1881): De l'atenuation des virus et de leur retour a la virulence. - C. Rend. Acad. Sci., 92: 429–435.
PersoneusG., CooperM.S., PercivalR.C. (1956): Studies on anthrax vaccine prepared from non-encapsulated variants of Bacillus anthracis. - Am. J. Vet. Res., 17: 153–156.
PetitT.L. (1985): Aluminum in human dementia. -Am. J. Kidney Dis., 6: 313–316.
PuzissM., ManningL.C., LynchJ.W., BarclayE., AbelowI., WrightG.C. (1963): Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures. - Appl. Microbiol., 11: 330–334.
ReapE.A., LawsonJ.W. (1987): The effects of dimethylglycine on the immune response of rabbits.- Abstr. Ann. Meeting, Am. Soc. Microbiol. E102, 120.
RobertsonD.L., LepplaS.H. (1986): Molecular cloning and expression in Escherichia coli of the lethal factor gene of Bacillus anthracis. - Gene, 44: 71–78.
RossJ.M. (1957): The pathogenesis of anthrax following the administration of spores by the respiratory route. - J. Pathol. Bacteriol., 73: 485–494.
SmithH., GallopR.C. (1956): The chemical basis of the virulence of Bacillus anthracis. VI. An extracellular immunising aggressin isolated from exudates of infected guinea pigs. - Br. J. Exp. Pathol., 37: 144–155.
SmithH., KeppieJ. (1954): Observations on experimental anthrax: demonstration of a specific lethal factor produced in vivo by Bacillus anthracis. -Nature (London) 173: 689.
SmithH., StonerH.B. (1967): Anthrax toxic complex.- Fed. Proc., 26: 1554–1557.
StanleyJ.L., SmithH. (1963): The three factors of anthrax toxin: their immunogenicity and lack of demonstrable enzymic activity. - J. Gen. Microbiol., 31: 329–337.
SterneM. (1939): The use of anthrax vaccines prepared from avirulent (uncapsulated) variants of Bacillus anthracis. - Onderstepoort J. Vet. Sci. Anim. Indust, 13: 307–312.
SterneM. (1939): The immunization of laboratory animals against anthrax. - Onderstepoort J. Vet. Sci. Anim. Indust. 13: 313–317.
SterneM. (1946): Avirulent anthrax vaccine. - Onderstepoort J. Vet. Sci. Anim., 21: 41–43.
SterneM., NicolJ., LambrechtsM.C. (1942): The effect of large-scale active immunisation against anthrax. - J. S. Afr. Vet. Med. Assoc. 13: 53.
ThorneC.B. (1985): Genetics of Bacillus anthracis. In L. Leive Ed., Microbiology — 1985. American Society for Microbiology, Washington, D.C., pp. 56–62.
TurellM.J., KnudsonG.B. (1987): Mechanical transmission of Bacillus anthracis by stable flies (Stomoxys calcitrans) and mosquitoes (Aedes aegypti and Aedes taeniorhynchus). - Infect. Immun., 55: 1859–1861.
TurnbullP.C.B. (1986): Thoroughly modern anthrax.- Bureau Hyg. Trop. Dis., 61: R1-R13.
TurnbullP.C.B., BrosterM.G., CarmanJ.A., MancheeR.J., MellingJ. (1986): Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.- Infect. Immun., 52: 356–363.
UchidaI., SekizakiT., HashimotoK., TerikadoN. (1985): Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid.- J. Gen. Microbiol., 131: 363–367.
VodkinM., LepplaS.H. (1983): Cloning of the protective antigen gene of Bacillus anthracis. - Cell, 34: 693–696.
WardM.K., McGannV.G., HoggeA.L.Jr., HuffM.L., KanodeR.G.Jr., RobertsE.O. (1965): Studies on anthrax infections in immunized guinea pigs. -J. Infect. Dis., 115: 59–67.
WarrenH.S., VogelF.R., ChedidL.A. (1986): Current status of immunological adjuvants. - Ann. Rev. Immunol., 4: 369–388.
WelkosS.L., KeenerT.J., GibbsP.H. (1986): Differences in susceptibility of inbred mice to Bacillus anthracis. - Infect. Immun., 51: 795–800.
Welkos S.L., Friedlander A.M. (1988): Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis, - Microbiol. Pathogen., in press.
WillsM.R., SavoryJ. (1985): Water content of aluminum, dialysis dementia, and osteomalacia. -Environ. Health Perspect., 63: 141–147.
WrightG.G. (1975): Anthrax toxin. In Microbiology — 1975, D. Schlessinger (Ed.) American Society For Microbiology, Washington, D.C., pp. 292–295.
YoungG.A.Jr., ZelleM.R., LincolnR.E. (1946): Respiratory pathogenicity of B. anthracis spores. I. Methods of study and observations on pathogenesis.- J. Infect. Dis., 79: 233–246.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ivins, B.E., Welkos, S.L. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 4, 12–19 (1988). https://doi.org/10.1007/BF00152686
Issue Date:
DOI: https://doi.org/10.1007/BF00152686